人参皂苷 Rg3 联合奥希替尼治疗一代EGFR-TKI 耐药型晚期非小细胞肺癌的疗效及安全性(1)

http://www.100md.com 2019年7月1日 《新医学》 20197

     【摘要】 目的 分析人參皂苷Rg3联合奥希替尼治疗一代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药型晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法 选择一代EGFR-TKI耐药型晚期NSCLC患者60例作为研究对象，将所选对象分为实验组和对照组。实验组患者给予人参皂苷Rg3联合奥希替尼治疗，对照组给予奥希替尼单药治疗。观察2组患者疗效、生存时间、生活质量和不良反应。结果 实验组治疗后客观缓解率为73.33%，对照组为63.33%，2组比较差异无统计学意义(P = 0.405);实验组患者中位无进展生存期(PFS)为16个月，优于对照组的13个月，2组比较差异有统计学意义(χ2 = 5.302，P = 0.021);2组患者不良反应均较轻，不良反应发生率比较差异无统计学意义(P > 0.05);2组患者治疗后生活质量评分较前提高，实验组生活质量评分改善高于对照组(t = 6.283，P < 0.001)。结论 人参皂苷Rg3联合奥希替尼治疗一代EGFR-TKI耐药型晚期NSCLC患者的疗效较好，延长PFS，不良反应可耐受，改善患者的生活质量。
, http://www.100md.com
    【关键词】 人参皂苷Rg3;奥希替尼;EGFR-TKI耐药型;非小细胞肺癌;疗效;安全性

    Clinical efficacy and safety of Ginsenoside Rg3 combined with Osimertinib in treatment of the first-generation EGFR-TKI-resistant advanced non-small cell lung cancer Jiang Guanming， Tan Qinquan， Liu Chun， Yao Mantian， Zeng Yihong， Yuan Haiji， Lin Shunhuan. Department of Oncology， Dongguan People’s Hospital， Dongguan 523059， China

    Corresponding author， Lin Shunhuan， E-mail： 1974269473@ qq. com
, 百拇医药
    【Abstract】 Objective To evaluate the clinical efficacy of Ginsenoside Rg3 combined with Osimertinib in the treatment of the first-generation EGFR-TKI-resistant advanced non-small cell lung cancer (NSCLC). Methods Sixty patients with EGFR-TKI-resistant advanced NSCLC were recruited in this study and randomly divided into the experimental and control groups. Patients in the experimental group were given with Ginsenoside Rg3 in combination with Osimertinib and those in the control group were treated with Osimertinib alone. The clinical efficacy， survival time， quality of life and adverse events were observed between two groups. Results The objective remission rate was 73.33% in the experimental group， which did not significantly differ from 63.33% in the control group (P = 0.405). In the experimental group， the median progression-free survival (PFS) was 16 months， significantly longer compared with 13 months in the control group (χ2 = 5.302， P = 0.021). The adverse events were mainly grade I and II in both groups. The incidence of adverse events did not significantly differ between two groups (P > 0.05). The quality of life scores were elevated in both groups after corresponding treatment. The quality of life score in the experimental group was significantly higher than that in the control group (t = 6.283，P < 0.001). Conclusions Ginsenoside Rg3 combined with Osimertinib is efficacious in the treatment of the first-generation EGFR-TKI-resistant advanced NSCLC， which can prolong the PFS， yield tolerable adverse events and enhance the quality of life of patients., 百拇医药(江冠铭?谭钦全?刘淳?姚满田?曾溢蕻?袁海姬?林顺欢)

第 1 2 3 4 页 下一页

    百拇医药网 http://www.100md.com/html/paper/0253-9802/2019/07/06.htm